There has been a resurgence of interest in psychedelics as researchers look to create alternative treatment solutions for a growing patient base.
Early clinical results, increased corporate and media support and a regulatory thaw of these Schedule I compounds have created the perfect framework for the industry to benefit from what psychedelics have to offer.
In the last few years, classic psychedelics have shown the potential to provide an improved, alternative treatment solution to a vast array of mental health indications - ranging from treatment-resistant depression and anxiety to PTSD.
MagicMed Industries is dedicated to being a part of the solution.
MagicMed's focus is on the development of the world's foremost library of psychedelic derivatives, called the Psybrary™.
With a vast library of individual molecules covered by several different chemical compound categories, MagicMed is pursuing partnerships with innovators in the industry to develop newly patented products.
These products will help tailor drug candidates to patients' needs and unlock the healing power of psychedelics.
MagicMed has finished it's initial derivative portfolio based on the structures of psilocybin and N,N-dimethyltryptamine (DMT). Research efforts continue to create additional patents and derivative portfolios based on MDMA, mescaline, LSD and ibogaine.
The scientific community is paying attention to the breakthrough potential of psychedelics.
Numerous studies by institutions including Johns Hopkins, UC Berkley, Imperial College, Heffter Research Institute, University of Toronto, and University of British Columbia have been investigating the benefits of therapy using psychedelics.
Building on these promising results, psychedelic pharmaceuticals need to be modified to have fewer side effects, better efficacy, and out of clinic applicability.
The Psybrary™ is set to contain a vast portfolio of psychedelic derivatives based on the structures of psilocybin, DMT, LSD, mescaline, ibogaine and MDMA.
Designed to be the leading provider of novel drug candidates for the biotechnology and pharmaceutical industries
Combining synthetic biology and chemistry enables the largest, most diverse portfolio of psychedelic derivatives possible
Extensive, robust patenting covers compositions, manufacturing, and uses for millions of possible drug candidates
PsyAI is a tool designed to streamline pharmaceutical design by predicting structure, manufacturing capabilities and pharmacological effects in an effort to accelerate the modernization of psychedelic medicine.
Given the volume of data that will be generated at various levels including compound, test results and patient profile, the use of PsyAI will be a critical tool to process that data and generate actionable insights for the psychedelic drug development process.
Each PsyAI module that is developed increases the value of a compound as a potential therapeutic by leveraging AI systems to reduce the time and cost of commercial development
Psychedelics have immense potential to treat several illnesses. Multiple psychedelic-based scientific studies and clinical trials have shown promising data to treat many mental health indications.
This includes diseases and disorders such as:
Patented molecules can address multiple psychological indications
MagicMed has filed patents in psilocybin/N.N-dimethyltryptamine (DMT) derivatives and will expand to other psychedelics
Platform play for the industry that does not cannibalize on sector market share
Revenue across the drug development stages with diversified upside potential
Licensing deals can be done with multiple partners
Designed to be quickly cash flow positive and to come to market for capital only upon accretive or transformative events
MagicMed announced today that it has completed the establishment of the psilocybin-derivatives patent portfolio of the PsybraryTM and the launch of the Candidate Selection program..
There has been significant interest in the psychedelic space and of the promise psychedelic molecules show in treating mental health conditions.
Current mental health treatment regimes are not a solution for everyone. Psychedelics offer a potential alternative treatments by acting via different mechanisms.
Further work is required to create novel drugs that have fewer side effects, better efficacy, and out of clinic applicability.
MagicMed Industries Inc. is working to provide this solution.